HELION BIOTECH

- Restoration of inherited immune defect by replacement therapy with recombinant human mannan-binding lectin (rhMBL)... - More than 10 independent publications since 2006 identify MBL deficiency as a very strong risk factor for neonatal infection and sepsis... - Complete US regulatory dossier allows for bridging directly into a Phase II clinical trial, targeting MBL deficient very preterm neonates

Also known as: Helion Biotech ApS

Primary location: Copenhagen N Denmark